Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis

European Heart Journal

Volumn 23, Issue 2, 2002, Pages 157-161

  Reyners, A K L ^a   Hazenberg, B P C ^a   Reitsma, W D ^a   Smit, A J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amyloidosis; Autonomic nervous system; Heart rate variability

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; LIFE EXPECTANCY; MALE; MORTALITY; PARAMETER; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; RR INTERVAL; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; FEMALE; HEART DISEASES; HEART RATE; HEART VENTRICLES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SERUM AMYLOID A PROTEIN;

EID: 0036401462     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2972     Document Type: Article

References (21)

1. Dubrey SW, Cha K, Anderson J et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141-57.
2. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: Colchicine, alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med 1997; 336: 1202-7.
3. Sezer O, Eucker J, Jakob C, Possinger K. Diagnosis and treatment of AL amyloidosis. Clin Nephrol 2000; 53: 417-23.
4. Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 1994; 8: 627-34.
5. Joss N, Mclaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. QJM 2000; 93: 535-42.
6. Gertz MA, Kyle RA. Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine 1991; 70: 246-56.
7. Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year follow-up of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993; 20: 2051-7.
8. Wallis MS, Stough DB IV. Extended survival of patients with primary systemic amyloidosis. Cutis 1992; 49: 143.
9. Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years and more) in 30 patients with primary (AL) amyloidosis. In: Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis 1998. New York: Parthenon Publishing Group, 1999: 151-3.
10. Cueto-Garcia L, Reeder GS, Kyle RA et al. Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985; 6: 737-43.
11. Hamer JP, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J 1992; 13: 623-7.
12. Berg AM, Anderson JJ, Chipkin SR et al. Autonomic neuropathy in AL (primary) amyloidosis and its effect on survival. Amyloid 1994; 1: 39-46.
13. Reyners AKL, Hazenberg BPC, Haagsma EB, Tio RA, Reitsma WD, Smit AJ. The assessment of autonomic function in patients with systemic amyloidosis: Methodological considerations. Amyloid 1998; 5: 193-9.
14. Husby G. Immunoglobulin-related (AL) amyloidosis. Clin Exp Rheumatol 1983; 1: 353-8.
15. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. Circulation 1996; 93: 1043-65.
16. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-84.
17. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-62.
18. Lombardi F, Mortara A. Heart rate variability and cardiac failure. Heart 1998; 80: 213-4.
19. Tsuji H, Venditti FJ, Manders ES et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994; 90: 878-83.
20. Malik M, Camm AJ, Janse MJ, Julian DG, Frangin GA, Schwartz PJ. Depressed heart rate variability identifies post-infarction patients who might benefit from prophylactic treatment with amiodarone: A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol 2000; 35: 1263-75.
21. Dekker JM, Crow RS, Folsom AR et al, Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: The ARIC study. Circulation 2000; 102: 1239-44.